

The 14th Annual Pharmacogenetics in Psychiatry Meeting

October 15, 2015

Omni King Edward Hotel, Toronto, Canada

Thursday, October 15, 2015

7:30 AM Continental Breakfast

8:15 AM Welcome and Introduction

SESSION I: PHARMACOGENETICS OF CLOZAPINE RESPONSE

Chair: Anil K. Malhotra

8:30 AM *Establishing the Characteristics of an Effective Pharmacogenetics Test for Clozapine Induced Agranulocytosis*
Moira Verbelen
King's College, London, UK

8:55 AM *An Epigenome-wide Association Study of Clozapine Use in Treatment-resistant Schizophrenia*
Eilis Hanlon
University of Exeter, England, UK

9:20 AM *Neurobiological Correlates of Clozapine Response in Patient-derived Neurons*
Rakesh Karmacharya
Harvard University, Massachusetts, USA

9:45 AM Break

SESSION II: PHARMACOGENETICS OF ANTIPSYCHOTIC DRUGS

Chair: James Kennedy

10:00 AM *Complex Genetic Overlap Between Schizophrenia Risk and Antipsychotic Response*
Douglas Ruderfer
Icahn School of Medicine at Mount Sinai, New York, USA

10:25 AM *Investigating the Functional Significance of Genome-wide Variants Associated with Antipsychotic Treatment Response*
Ellen Ovenden
Stellenbosch University, South Africa, Africa

10:50 AM *Schizophrenia risk variant at DRD2 locus predicts antipsychotic treatment response in first episode psychosis*
Jianping Zhang
The Zucker Hillside Hospital, New York, USA

11:15 AM *Preliminary Evidence for Association of Genome-wide Significant DRD2 Schizophrenia Risk Variant with Clozapine Response*
Eric Huang

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

11:40 AM *Pharmacogenetics of Antipsychotic-induced Weight Gain in Multiple Drug-naïve Cohorts*
Todd Lencz
The Zucker Hillside Hospital, New York, USA

12:05 PM Lunch on Own

SESSION III: PHARMACOGENETICS OF MOOD & ANXIETY DISORDERS

Chair: David Goldman

1:30 PM *Epigenetics in Anxiety Disorders*
Katharina Domschke
University of Würzburg, Germany

1:55 PM *Common Genetic Markers for Lithium Response in Bipolar Disorder*
Francis J. McMahon
National Institute of Mental Health Intramural Research Program, Maryland, USA

2:20 PM *Genetics of Long-term Treatment Outcome in Bipolar Disorder*
Alessandro Serretti
University of Bologna, Italy

2:45 PM *Genome-wide Association Analyses in Clinical Response to Duloxetine and Placebo in Major Depression*
Daniel Müller
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

3:10 PM *Genome-wide Association Study of Lithium Response in a Prospective Trial Sample- The Pharmacogenomics of Bipolar Disorder Study*
John Kelsoe
University of California, San Diego, California, USA

3:35 PM Break

SESSION IV: THE CRESTAR CONSORTIUM: DEVELOPMENT OF BIOMARKERS FOR SCHIZOPHRENIA

Chair: David A. Collier

Co-Chair: Dan Rujescu

3:45 PM *The CRESTAR Consortium: Overview*
David A. Collier
Eli Lilly and Company, LTD

4:00 PM *Pharmacogenomics of Agranulocytosis*
Dan Rujescu
Martin-Luther-University Halle-Wittenberg

- 4:20 PM *Genomics of Treatment-resistant Schizophrenia*
Sophie Legge
MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University
- 4:45 PM *Predicting Models Within Pharmacogenomics*
Cathryn Lewis, Ph.D.
King's College London
- 5:10 PM Meeting Adjourns
- 5:30 PM Poster Session and Reception